Exact Mass: 182.0435

Exact Mass Matches: 182.0435

Found 39 metabolites which its exact mass value is equals to given mass value 182.0435, within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error 0.0002 dalton.

1-Methyluric acid

1-methyl-2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-trione

C6H6N4O3 (182.044)


1-Methyluric acid is one of the three main theophylline metabolites in man. 1-Methyluric acid is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID: 11712316, 15833286, 3506820, 15013152, 4039734, 9890610) [HMDB] 1-Methyluric acid is one of the three main theophylline metabolites in man. 1-Methyluric acid is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline, and theobromine). Methyluric acids can be distinguished from uric acid via simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase, or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 superfamily, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis (PMID:11712316, 15833286, 3506820, 15013152, 4039734, 9890610).

   

7-Methyluric acid

7,9-dihydro-7-methyl-1H-purine-2,6,8(3H)-trione

C6H6N4O3 (182.044)


7-Methyluric acid is the minor urinary metabolites of caffeine. Caffeine is metabolized mainly in the liver undergoing demethylation and oxidation. [HMDB] 7-Methyluric acid is the minor urinary metabolites of caffeine. Caffeine is metabolized mainly in the liver undergoing demethylation and oxidation.

   

9-Methyluric acid

9-methyl-2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-trione

C6H6N4O3 (182.044)


9-Methyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 9-Methyluracil is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID: 11712316, 15833286, 3506820, 15013152) [HMDB] 9-Methyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 9-Methyluracil is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID:11712316, 15833286, 3506820, 15013152).

   

3-Methyluric acid

3-methyl-2,3,6,7,8,9-hexahydro-1H-purine-2,6,8-trione

C6H6N4O3 (182.044)


3-Methyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 3-Methyluracil is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID: 11712316, 15833286, 3506820, 15013152) [HMDB] 3-Methyluric acid is a methyl derivative of uric acid, found occasionally in human urine. 3-Methyluracil is one of the purine components in urinary calculi. Methylated purines originate from the metabolism of methylxanthines (caffeine, theophylline and theobromine). Methyluric acids are indistinguishable from uric acid by simple methods routinely used in clinical laboratories, requiring the use of high-performance liquid chromatography (HPLC). Purine derivatives in urinary calculi could be considered markers of abnormal purine metabolism. The content of a purine derivative in stone depends on its average urinary excretion in the general population, similarity to the chemical structure of uric acid, and content of the latter in stone. This suggests that purines in stones represent a solid solution with uric acid as solvent. It is also plausible that methylxanthines, ubiquitous components of the diet and drugs, are involved in the pathogenesis of urolithiasis. Caffeine is metabolized via successive pathways mainly catalyzed by CYP1A2, xanthine oxidase or N-acetyltransferase-2 to give 14 different metabolites. CYP1A2 activity shows an inter-individual variability among the population. CYP1A2, an isoform of the CYP1A cytochrome P450 super-family, is involved in the metabolism of many drugs and plays a potentially important role in the induction of chemical carcinogenesis. (PMID: 11712316, 15833286, 3506820, 15013152).

   

7-Methyluric acid

7,9-dihydro-7-methyl-1H-purine-2,6,8(3H)-trione

C6H6N4O3 (182.044)


   

3,3-Disulfanediylbis(propan-1-ol)

3,3-Disulfanediylbis(propan-1-ol)

C6H14O2S2 (182.0435)


   

9-Methyluric acid

7,9-dihydro-9-Methyl-1H-purine-2,6,8(3H)-trione

C6H6N4O3 (182.044)


   

1-Methyluric acid

1-Methyluric acid

C6H6N4O3 (182.044)


An oxopurine that is 7,9-dihydro-1H-purine-2,6,8(3H)-trione substituted by a methyl group at N-1. It is one of the metabolites of caffeine found in human urine.

   

3-Methyluric acid; LC-tDDA; CE10

3-Methyluric acid; LC-tDDA; CE10

C6H6N4O3 (182.044)


   

3-Methyluric acid; LC-tDDA; CE20

3-Methyluric acid; LC-tDDA; CE20

C6H6N4O3 (182.044)


   

3-Methyluric acid; LC-tDDA; CE30

3-Methyluric acid; LC-tDDA; CE30

C6H6N4O3 (182.044)


   

3-Methyluric acid; LC-tDDA; CE40

3-Methyluric acid; LC-tDDA; CE40

C6H6N4O3 (182.044)


   

1-Methyluric acid; LC-tDDA; CE10

1-Methyluric acid; LC-tDDA; CE10

C6H6N4O3 (182.044)


   

1-Methyluric acid; LC-tDDA; CE20

1-Methyluric acid; LC-tDDA; CE20

C6H6N4O3 (182.044)


   

1-Methyluric acid; LC-tDDA; CE30

1-Methyluric acid; LC-tDDA; CE30

C6H6N4O3 (182.044)


   

1-Methyluric acid; LC-tDDA; CE40

1-Methyluric acid; LC-tDDA; CE40

C6H6N4O3 (182.044)


   

7-Methyluric acid; LC-tDDA; CE10

7-Methyluric acid; LC-tDDA; CE10

C6H6N4O3 (182.044)


   

7-Methyluric acid; LC-tDDA; CE20

7-Methyluric acid; LC-tDDA; CE20

C6H6N4O3 (182.044)


   

7-Methyluric acid; LC-tDDA; CE30

7-Methyluric acid; LC-tDDA; CE30

C6H6N4O3 (182.044)


   

7-Methyluric acid; LC-tDDA; CE40

7-Methyluric acid; LC-tDDA; CE40

C6H6N4O3 (182.044)


   

3-Methyluric acid; AIF; CE30; CorrDec

3-Methyluric acid; AIF; CE30; CorrDec

C6H6N4O3 (182.044)


   

3-Methyluric acid; AIF; CE0; MS2Dec

3-Methyluric acid; AIF; CE0; MS2Dec

C6H6N4O3 (182.044)


   

3-Methyluric acid; AIF; CE10; MS2Dec

3-Methyluric acid; AIF; CE10; MS2Dec

C6H6N4O3 (182.044)


   

3-Methyluric acid; AIF; CE30; MS2Dec

3-Methyluric acid; AIF; CE30; MS2Dec

C6H6N4O3 (182.044)


   

1-Methyluric acid; AIF; CE0; CorrDec

1-Methyluric acid; AIF; CE0; CorrDec

C6H6N4O3 (182.044)


   

1-Methyluric acid; AIF; CE10; CorrDec

1-Methyluric acid; AIF; CE10; CorrDec

C6H6N4O3 (182.044)


   

1-Methyluric acid; AIF; CE30; CorrDec

1-Methyluric acid; AIF; CE30; CorrDec

C6H6N4O3 (182.044)


   

1-Methyluric acid; AIF; CE10; MS2Dec

1-Methyluric acid; AIF; CE10; MS2Dec

C6H6N4O3 (182.044)


   

1-Methyluric acid; AIF; CE30; MS2Dec

1-Methyluric acid; AIF; CE30; MS2Dec

C6H6N4O3 (182.044)


   

7-Methyluric acid; AIF; CE0; MS2Dec

7-Methyluric acid; AIF; CE0; MS2Dec

C6H6N4O3 (182.044)


   

7-Methyluric acid; AIF; CE10; MS2Dec

7-Methyluric acid; AIF; CE10; MS2Dec

C6H6N4O3 (182.044)


   

7-Methyluric acid; AIF; CE30; MS2Dec

7-Methyluric acid; AIF; CE30; MS2Dec

C6H6N4O3 (182.044)


   

3-METHYLURIC ACID

4,9-dihydro-3-Methyl-1H-purine-2,6,8(3H)-trione

C6H6N4O3 (182.044)


   

4-amino-5-nitropyridine-3-carboxamide

4-amino-5-nitropyridine-3-carboxamide

C6H6N4O3 (182.044)


   

3,6-DIOXA-1,8-OCTANEDITHIOL

3,6-DIOXA-1,8-OCTANEDITHIOL

C6H14O2S2 (182.0435)


   

1,2-Dithiocane-3,8-diol

1,2-Dithiocane-3,8-diol

C6H14O2S2 (182.0435)


   

6-OXO-1,6-DIHYDRO-PYRAZINE-2,3-DICARBOXYLIC ACID DIAMIDE

6-OXO-1,6-DIHYDRO-PYRAZINE-2,3-DICARBOXYLIC ACID DIAMIDE

C6H6N4O3 (182.044)


   

Propyl propane thiosulfonate

Propyl propane thiosulfonate

C6H14O2S2 (182.0435)


   

Methyluric acid

Methyluric acid

C6H6N4O3 (182.044)